Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates

Core Insights - Century Therapeutics is advancing its pipeline of induced pluripotent stem cell (iPSC)-derived therapies targeting autoimmune diseases and cancer, with a focus on type 1 diabetes and a strong financial position following a $135 million private placement [2][10] Financial Performance - For the year ended December 31, 2025, collaboration revenue increased significantly to $109.2 million from $6.6 million in 2024, reflecting successful partnerships [10] - Research and development (R&D) expenses decreased to $95.7 million from $107.2 million in 2024, attributed to reduced personnel and manufacturing costs [10] - General and administrative (G&A) expenses also fell to $24.0 million from $33.2 million in 2024, primarily due to lower legal fees and other cost reductions [10] - The net loss for 2025 was $9.6 million, a substantial improvement from a net loss of $126.6 million in 2024 [10][16] Pipeline Developments - CNTY-813, the lead program for type 1 diabetes, is in IND-enabling studies, with an IND submission expected in Q4 2026 and initial clinical data anticipated in the second half of 2027 [5][6] - CNTY-308, a CD19-targeted CAR-iT cell therapy, is on track to enter clinical trials in 2026, demonstrating promising preclinical results [5][6] - The company expects to release updated preliminary clinical data from the ongoing CARAMEL study in 2026, which has shown early signs of clinical response in autoimmune diseases [6] Corporate Developments - Century Therapeutics appointed two new members to its Board of Directors in December 2025, enhancing its governance structure [10] - The company’s cash position as of December 31, 2025, was $117.1 million, down from $220.1 million in 2024, but sufficient to support operations into Q1 2029 [10][13]